MDL For Contaminated Valsartan Created; 40 Cases Transferred To New Jersey Court

(February 15, 2019, 2:17 PM EST) -- WASHINGTON, D.C. — A federal judicial panel on Feb. 14 centralized in a multidistrict litigation 40 federal personal injury, economic injury and third-party payer lawsuits alleging that various defendants made or marketed the generic blood pressure drug valsartan that contained contaminants that can possibly cause cancer or liver damage (In Re:  Valsartan N-Nitrosodimethylamine [NDMA] Contamination Products Liability Litigation, MDL Docket No. 2875, JPMDL)....

Attached Documents

Related Sections